ArticleAddiction science & clinical practice2021
Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial.
Article in Addiction science & clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder: A Randomized Controlled Trial
Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Factors that distinguish opioid withdrawal during induction with buprenorphine microdosing: a configurational analysis.Addiction science & clinical practice · 2022Pooled it
- MiBUP: A pilot randomized controlled trial of low-dose initiation of buprenorphine for opioid use disorder: Design and rationale.Contemporary clinical trials communications · 2026Article
- High-dose buprenorphine inductions in hospital settings.American journal of medicine open · 2025Article
- Emergency department management of opioid use disorder in pediatric patients.Journal of the American College of Emergency Physicians open · 2024Article
- Initiation of Low-Dose Intravenous Buprenorphine for Opioid Use Disorder: A Case Series and Literature Review.Cureus · 2024Article
- Considerations when prescribing opioid agonist therapies for people living with HIV.Expert review of clinical pharmacology · 2024Review
- Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder.Addiction science & clinical practice · 2024Article
- Low-dose overlap initiation with split tablets of buprenorphine in intubated intensive care unit patients with opioid use disorder.Harm reduction journal · 2024Article
- Low-dose buprenorphine initiation and treatment continuation among hospitalized patients with opioid dependence: A retrospective cohort study.Journal of substance use and addiction treatment · 2024Article
- A Guide to Expanding the Use of Buprenorphine Beyond Standard Initiations for Opioid Use Disorder.Drugs in R&D · 2023Review
- Low-Dose Initiation of Buprenorphine: A Narrative Review.Current pain and headache reports · 2023Review
- History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder.Drug and alcohol dependence reports · 2023Review
- Case report: acute care management of severe opioid withdrawal with IV fentanyl.Addiction science & clinical practice · 2022Article
- Blister-Packing of 2 mg Buprenorphine Monoproduct as a Patient-Centered Method of Microdosing for Buprenorphine Induction.Clinical drug investigation · 2021Article
- Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients-A Critical Review.Frontiers in pharmacology · 2021Review
- Using Microdosing to Induct Patients Into a Long-Acting Injectable Buprenorphine Depot Medication in Low Threshold Community Settings: A Case Study.Frontiers in pharmacology · 2021Article
- Balancing transition and readmission: a comparative study of low-dose vs standard buprenorphine initiation for medically managed opioid withdrawal.Journal of addictive diseasesArticle
- Rapid Overlap Initiation Protocol Using Low Dose Buprenorphine for Opioid Use Disorder Treatment in an Outpatient Setting: A Case Series.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBuprenorphine/naloxone (Suboxone) is a current first-line treatment for opioid use disorder (OUD). The standard induction method of buprenorphine/naloxone requires patients to be abstinent from opioids and therefore experience withdrawal symptoms prior to induction, which can be a barrier in starting treatment. Rapid micro-induction (micro-dosing) involves the administration of small, frequent does of buprenorphine/naloxone and removes the need for a period of withdrawal prior to the start of treatment. This study aims to compare the effectiveness and safety of rapid micro-induction versus standard induction of buprenorphine/naloxone in patients with OUD.
methodsThis is a randomized, open-label, two-arm, superiority, controlled trial comparing the safety and effectiveness of rapid micro-induction versus standard induction of buprenorphine/naloxone for the treatment of OUD. A total of 50 participants with OUD will be randomized at one Canadian hospital. The primary outcome is the completion of buprenorphine/naloxone induction with low levels of withdrawal. Secondary outcomes are treatment retention, illicit drug use, self-reported drug use behaviour, craving, pain, physical health, safety, and client satisfaction. DISCUSSION: This is the first randomized controlled trial to compare the effectiveness and safety of rapid micro-induction versus standard induction of buprenorphine/naloxone. This study will thereby generate evidence for a novel induction method which eliminates substantial barriers to the use of buprenorphine/naloxone in the midst of the ongoing opioid crisis. Trial registration ClinicalTrials.gov, NCT04234191; date of registration: January 21, 2020; https://clinicaltrials.gov/ct2/show/NCT04234191.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.